Systemic fungal infections in renal diseases.
Invasive fungal infections are a major challenge in the management of immunocompromised patients and those with renal dysfunction. These challenges are due to the immense morbidity and mortality in such situations. Also the management strategies for invasive mycosis in patients with renal dysfunction have narrow safety profile and involve high-cost. In this review we will discuss the issues involved in the management of invasive mycosis in the patients with renal dysfunction in the form of acute renal failure, chronic kidney disease, dialysis dependency of renal transplant recipients. We also emphasize that the use of Intravenous Liposomal Amphoterecin appears to be an effective alternative to the conventional Amphoterecin B for the treatment of invasive fungal infections in patients with renal dysfunction due to its greatly improved tolerability profile. Commercially two true liposomal preparations (Fungisome and Ambisome) are available. Judgement about the preferred formulation should be made on the basis of disease morbidity, severity of renal dysfunction and the cost involved.
Gandhi
B V
BV
Department of Nephrology, Jaslok Hospital, Mumbai, India.
Bahadur
M M
MM
Dodeja
H
H
Aggrwal
V
V
Thamba
A
A
Mali
M
M
D000935:Antifungal Agents / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D016030:Kidney Transplantation / Q000009:adverse effects; D009181:Mycoses / Q000150:complications* / Q000188:drug therapy*; D051437:Renal Insufficiency / Q000150:complications*
D000935:Antifungal Agents